Department of Protein Analytical Chemistry, Genentech, Inc., South San Francisco, CA 94080, USA.
Biotechnol Prog. 2012 Nov-Dec;28(6):1526-33. doi: 10.1002/btpr.1620. Epub 2012 Nov 1.
The ability to detect and quantitate a variety of components in solution has become increasingly important in carrying out efficient and rigorous validation studies for biopharmaceutical manufacturing processes. Here, we demonstrate the general applicability of NMR spectroscopy for the identification and quantitation of leachables and other impurities in protein-based drugs, at low levels previously unattainable in protein-containing solutions. With improved NMR technology (i.e., CryoProbes) and the application of a Carr-Purcell-Meiboom-Gill pulse sequence (CPMG) to attenuate protein signals, we have been able to use NMR to quantify impurities in a protein-based biopharmaceutical product at ~1 μg mL(-1) . The data indicate that NMR spectra can be used to quantitate a range of impurities, from small molecule components to higher molecular weight leachables, without removing protein from solution. Furthermore, quantitation of impurities by NMR is reliable and accurate enough for biopharmaceutical process validation, even for high molecular weight extractables whose structures are not precisely known.
在进行高效、严格的生物制药制造工艺验证研究时,能够检测和定量分析溶液中的各种成分变得越来越重要。在这里,我们证明了 NMR 光谱法在鉴定和定量检测蛋白质药物中的浸出物和其他杂质方面的通用性,其能够检测到以前在含蛋白质溶液中无法达到的低水平杂质。通过改进 NMR 技术(即 CryoProbes)和应用 Carr-Purcell-Meiboom-Gill 脉冲序列(CPMG)来衰减蛋白质信号,我们已经能够使用 NMR 技术在 ~1 μg mL(-1) 的浓度下定量检测蛋白质生物制药产品中的杂质。数据表明,NMR 谱可以用于定量检测各种杂质,从小分子成分到更高分子量的浸出物,而无需从溶液中去除蛋白质。此外,NMR 定量检测杂质的方法对于生物制药工艺验证是可靠和准确的,即使是对于结构不完全清楚的高分子量萃取物也是如此。